Email this article DISSOCIATION OF BIOCHEMICAL AND TUMOR-SUPRESSIVE EFFECTS OF SOMATOSTATIN ANALOGS
- Authors: Dreval’ A.V.1,2, Ilovayskaya I.A.1,2, Pokramovich Y.G.1,2, Stashuk G.A.1,2, Tishenina R.S.1,2
-
Affiliations:
- Moscow Regional Research and Clinical Institute (MONIKI)
- 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
- Issue: No 32 (2014)
- Pages: 97-100
- Section: CLINICAL CASES
- URL: https://almclinmed.ru/jour/article/view/141
- DOI: https://doi.org/10.18786/2072-0505-2014-32-97-100
- ID: 141
Cite item
Full Text
Abstract
Normalization of the growth hormone and IGF-1 levels during somatostatin analogs treatment usually is a predictor of somatotropinoma volume reduction. However, dissociation of biochemical and tumor-supressive effects of somatostatin analogs was also noted. We represent the female patient who showed reduction of the GH levels from 34.3 to 3.1 ng/ml and IGF-1 levels from 796 to 415 ng/ml (the gender and age upper normal limit 262 ng/ml) within 36 months treatment with maximum doses of somatostatin analogs (octreotide LAR 40 mg). Despite the lack of biochemical control of acromegaly, progressive decrease of tumor volume by 44 – 64 – 73% from initial volume (during 12 – 24 – 36 months of treatment) was noted. This case shows that it is possible to expect considerable reduction of somatotropinoma volume during treatment with somatostatin analogs even without achievement of complete control over GH and IGF-1 secretion.
About the authors
A. V. Dreval’
Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Email: fake@neicon.ru
MD, PhD, Professor, Head of the Department of Therapeutic Endocrinology, MONIKI Россия
I. A. Ilovayskaya
Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Author for correspondence.
Email: irena.ilov@yandex.ru
PhD, Assistant Professor, senior scientific worker, Department of Therapeutic Endocrinology, MONIKI Россия
Yu. G. Pokramovich
Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Email: fake@neicon.ru
physician, Department of Therapeutic Endocrinology, MONIKI Россия
G. A. Stashuk
Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Email: fake@neicon.ru
MD, PhD, chief scientific worker, Department of X-ray Diagnostics, MONIKI
РоссияR. S. Tishenina
Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Email: fake@neicon.ru
MD, PhD, Professor, Head of the Chemical and Hormonal Laboratory,
MONIKI
References
- Пронин ВС, Молитвословова НН. Акромегалия. Этиология, патогенез, клиника, диагностика, лечение. М.; 2009. (Pronin VS, Molitvoslovova NN. Acromegaly: etiology, pathogenesis, clinical features, diagnosis, treatment. Moscow; 2009. Russian).
- Cook DM, Ezzat S, Katznelson L, Kleinberg DL, Laws ER Jr, Nippoldt TB, Swearingen B, Vance ML; AACE Acromegaly Guidelines Task Force. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract. 2004;10(3):213-25.
- Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A; Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509-17.
- Bevan JS. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005;90(3):1856-63.
- Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab. 2009;94(10): 3746-56.
- Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol. 2005;152(3):379-87.
Supplementary files
